Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 15 de 15
Filtrar
1.
Rom J Intern Med ; 55(1): 44-52, 2017 Mar 01.
Artigo em Inglês | MEDLINE | ID: mdl-28103201

RESUMO

BACKGROUND & AIMS: Considering the ability of anti-TNF alpha drugs to lower the burden intestinal inflammation in patients with inflammatory bowel disease (IBD), and the similarity between IBD and ankylosing spondylitis (AS) regarding inflammatory intestinal involvement, we aimed to investigate the impact of anti-TNF alpha biologic therapy on subclinical intestinal inflammation in AS patients. METHODS: Between January 2008 and December 2013, 38 AS patients and 23 controls were enrolled in the study and investigated with small bowel videocapsule endoscopy examination and ileocolonoscopy. Each tertile of the small bowel (proximal, mid and distal) was assessed by calculating the Lewis score based on the image stream. RESULTS: The Lewis scores were significantly higher in the AS group compared to controls (580.9 ± 818 vs. 81 ± 121, p<0.001). 16 patients (42.1%) were on anti-TNF alpha therapy (Adalimumab (n = 5), Infliximab (n = 5) or Etanercept (n = 6)).31.3% of them used NSAIDs simultaneously, compared with 77.3% of the other patients (p<0.01). Their Lewis scores were lower compared to the other patients for the entire small bowel (306 ± 164 vs. 790 ± 1038, p = 0.015), its proximal and distal tertiles (238 ± 154 vs. 560 ± 543, p = 0.021, and 140 ± 189 vs. 300 ± 220, p = 0.027, respectively). The Lewis score was also lower in patients receiving Adalimumab/Infliximab compared to those on Etanercept for the entire bowel and its distal tertile (262 ± 165 vs. 380 ± 148, p = 0.069 and 62 ± 101 vs. 273 ± 236, p = 0.060, respectively). CONCLUSION: Anti-TNF alpha therapy in patients with AS reduces the subclinical intestinal inflammation, but the magnitude seems to depend upon the class anti-TNF alpha agent used (Clinical Trials. gov NCT00768950).


Assuntos
Antirreumáticos/uso terapêutico , Fármacos Gastrointestinais/uso terapêutico , Doenças Inflamatórias Intestinais/tratamento farmacológico , Mucosa Intestinal/patologia , Espondilite Anquilosante/tratamento farmacológico , Fator de Necrose Tumoral alfa/antagonistas & inibidores , Adalimumab/administração & dosagem , Adulto , Anti-Inflamatórios não Esteroides/administração & dosagem , Cápsulas Endoscópicas , Colonoscopia/métodos , Quimioterapia Combinada , Etanercepte/administração & dosagem , Feminino , Hospitais Universitários , Humanos , Doenças Inflamatórias Intestinais/complicações , Doenças Inflamatórias Intestinais/diagnóstico , Infliximab/administração & dosagem , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Índice de Gravidade de Doença , Espondilite Anquilosante/complicações , Espondilite Anquilosante/diagnóstico , Resultado do Tratamento
2.
Rom J Intern Med ; 54(2): 113-20, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-27352440

RESUMO

Mast cells proteases, tryptase and chymase are directly involved in the growth and progression of solid tumors due to their important role in tumor angiogenesis. We examined the density of tryptase positive mast cells and the mean density of new blood vessels in gastric malignant tumors of patients with and without Helicobacter pylori infection, using immunohistochemical staining for tryptase (for mast cells) and CD 105 (for new vessels). Tryptase and CD 105 expression was detected in gastrectomy specimens. In this study, mast cell density correlates with angiogenesis and the growth and progression of gastric cancer. It also shows that the participation of Helicobacter pylori infection in the growth and progress of gastric neoplasia is due to an increase of peritumoral angiogenesis, with subsequent local and distant tumor spread and perivascular growth, but without perineural and nodal involvement.


Assuntos
Adenocarcinoma/enzimologia , Adenocarcinoma/patologia , Antígenos CD/metabolismo , Biomarcadores Tumorais/metabolismo , Mastócitos/metabolismo , Neovascularização Patológica , Receptores de Superfície Celular/metabolismo , Neoplasias Gástricas/enzimologia , Neoplasias Gástricas/patologia , Triptases/metabolismo , Adenocarcinoma/metabolismo , Adenocarcinoma/microbiologia , Adenocarcinoma/cirurgia , Adulto , Idoso , Estudos de Casos e Controles , Endoglina , Feminino , Gastrectomia , Infecções por Helicobacter/complicações , Helicobacter pylori/isolamento & purificação , Humanos , Masculino , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Valor Preditivo dos Testes , Prognóstico , Estudos Retrospectivos , Fatores de Risco , Sensibilidade e Especificidade , Neoplasias Gástricas/metabolismo , Neoplasias Gástricas/microbiologia , Neoplasias Gástricas/cirurgia
3.
Rom J Intern Med ; 53(3): 227-36, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-26710498

RESUMO

BACKGROUND: Gastric cancer continues to be a platoon leader of mortality causes. A significant number of recent studies show direct or indirect involvement of mast cells (MC), with a complex role both pro- and anti-tumor growth. AIM: To objectify the correlations between expression of MC and presence of Helicobacter pylori (HP) infection depending on neoplastic nature of the gastric damage. SUBJECTS AND METHODS: The study was carried out on archival samples of gastric wall from 30 patients with gastric cancer versus 30 age and sex-matched subjects with gastric surgery for non-neoplastic diseases. The inclusion criteria for the case group were histologically proven stage T3/T4 malignancies with regional lymph node metastases. For each case of the study group, distribution and number of MC tryptase positive (DMC-TP) were analyzed in five different areas from the same gastrectomy specimen: intratumor area, deep and side tumor invasion front, normal gastric tissue sample 5-10 cm or more distant from the tumor and furthest resection margin. RESULTS: Independently of HP infection, the study recorded a significantly lower value of DMC-TP in male patients. In regions with inflammatory lesions and preneoplastic changes and in control cases with non-gastric neoplasia, the DMC-TP level was higher than controls with HP-related inflammatory pathology, thus removing bacterial etiology from the forefront of MC mobilizing causes. CONCLUSION: The presence of H. pylori infection was not found to cause significant changes in terms of mobilizing mast cells in the gastric wall with advanced tumors, with minimal stage III TNM.


Assuntos
Infecções por Helicobacter/patologia , Helicobacter pylori , Mastócitos/fisiologia , Neoplasias Gástricas/microbiologia , Neoplasias Gástricas/patologia , Triptases/metabolismo , Estudos de Casos e Controles , Contagem de Células , Feminino , Gastrectomia , Infecções por Helicobacter/complicações , Infecções por Helicobacter/enzimologia , Humanos , Masculino , Pessoa de Meia-Idade , Neoplasias Gástricas/enzimologia
4.
Rom J Intern Med ; 53(1): 50-3, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-26076561

RESUMO

BACKGROUND AND AIMS: Colon polypectomy decreases the incidence of colorectal cancer and related mortality. Several factors such as the size, location and type of polyp as well as endoscopist experience have been shown to correlate with the risk of ensuing procedure-related complications. This study aims to evaluate the impact of polyp and endoscopist-related factors on the rate of postpolypectomy complication in a real-life setting. METHODS: During the study period all polypectomies performed in our unit were reported on a standard form that included data on polyp type (flat, sessile, pedunculated), size, location in the colon, resection method, endoscopist volume and procedure-related complications arising up to 30 days. The main outcome was the complication rate of polypectomies. The factors that associated with a higher risk of complications were assessed on univariate and multivariate analysis. RESULTS: 244 polyp resections from 95 patients were included in the analysis. 199 polyps were resected by low-volume endoscopists (44.7%) and 135 polypectomies were performed by high-volume endoscopists (55.3%). On multivariate analysis only polyp size correlated with the risk of procedure-related complications. CONCLUSION: Polyp size is the most important risk factor for procedure-related complications. Both high and low-volume endoscopists have a low overall rate of serious complications.


Assuntos
Pólipos do Colo/patologia , Pólipos do Colo/cirurgia , Colonoscopia/efeitos adversos , Humanos , Estudos Prospectivos , Fatores de Risco
5.
Curr Health Sci J ; 41(1): 70-72, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-30151253

RESUMO

This case report describes a gastric small submucosal tumor endosonographically resembling a gastrointestinal stromal tumor (GIST). The presence of calcifications inside prompted for the surgical excision, and the pathologic examination revealed in fact the presence of a glomangioma (glomus tumor). The presented case is an illustration of the fact that not all masses arising from the muscularis propria layer are GISTs, and the endosonographer must always think of alternative diagnoses.

6.
Rom J Intern Med ; 50(1): 7-11, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-22788088

RESUMO

Gastrointestinal stromal tumors (GISTs) have been a topic of increasing interest since the discovery of their cellular activation pathway via the receptor for tyrosine kinase (KIT) leading to the possibility of targeted molecular therapy in the form of imatinib mesylate. Endoscopic diagnostic and therapeutic possibilities have also been developing at a rapid pace in recent years. Endoscopic ultrasonography (EUS) allows for an accurate assessment of submucosal tumors and can provide tissue samples for diagnostic purposes using fine needle aspiration techniques. Several newer endoscopic techniques, including contrast enhanced EUS and endoscopic submucosal dissection, have also proven useful in the management of GISTs. Although the many recent studies have focused on the role of endoscopy in diagnosing and treating GISTs, we still need better evidence in order to formulate accurate guidelines.


Assuntos
Endoscopia Gastrointestinal/métodos , Tumores do Estroma Gastrointestinal/diagnóstico , Tumores do Estroma Gastrointestinal/cirurgia , Biópsia por Agulha Fina , Tomada de Decisões , Diagnóstico Diferencial , Endossonografia , Humanos
7.
Rom J Intern Med ; 49(4): 257-65, 2011.
Artigo em Inglês | MEDLINE | ID: mdl-22568270

RESUMO

UNLABELLED: Endoscopic removal of colon polyps is the main tool in colorectal cancer prevention programs. Although several quality indicators and guidelines have been proposed, polypectomy practices are still subject to great variation among endoscopist and little data is available regarding polypectomy practices in real life settings. METHODS: The records of the 1061 screening colonoscopies performed in 2010 in a tertiary care teaching hospital in Bucharest were reviewed and all colonoscopies where at least one polyp was detected were selected for analysis. The number of detected polyps, the resection rate and method used for polypectomy were studied and compared to colonoscopy quality indicators previously reported in literature. RESULTS: 941 polyps were detected in 395 patients. Invasive colorectal cancer was found in 42 patients. 548 polyps (58.23%) were removed endoscopically, with at least one polyp being resected in 283 patients (71.5%), resulting in a polypectomy rate of 26.67% in the entire study population. Cold forceps resection was the most commonly used method for the resection of polyps less than 5 mm in size, while for larger polyps hot snare was the preferred method. Concomitant invasive carcinoma and a larger number of polyps were predictive of incomplete removal of all detected polyps. CONCLUSION: Most quality indicators were met in our study group, with suboptimal performance regarding histological documentation of detected polyps and establishing a polyp-free colon.


Assuntos
Pólipos do Colo , Colonoscopia/métodos , Neoplasias Colorretais , Programas de Rastreamento/estatística & dados numéricos , Guias de Prática Clínica como Assunto/normas , Padrões de Prática Médica/estatística & dados numéricos , Pólipos do Colo/diagnóstico , Pólipos do Colo/patologia , Pólipos do Colo/cirurgia , Neoplasias Colorretais/diagnóstico , Neoplasias Colorretais/patologia , Neoplasias Colorretais/prevenção & controle , Intervalo Livre de Doença , Intervenção Médica Precoce/métodos , Feminino , Hospitais de Ensino/estatística & dados numéricos , Humanos , Masculino , Pessoa de Meia-Idade , Invasividade Neoplásica , Indicadores de Qualidade em Assistência à Saúde/estatística & dados numéricos , Romênia
8.
Rom J Intern Med ; 48(3): 239-47, 2010.
Artigo em Inglês | MEDLINE | ID: mdl-21528749

RESUMO

In our days, Helicobacter pylori is considered to be the bacterium responsible for the most frequent and persistent chronic infection worldwide, involving half of the entire world population. Untreated, the infection is lasting for the whole life. In Romania, the number of carrying people is variable between 90-94%, while in western countries, the prevalence of this infection is much lower, under 50-60%, with a high tendency to decrease, due both to the higher socio-economic level and to advanced methods of diagnosis and treatment, with a special focus on prevention. Because a percentage of 10-11% of the infected people develop in time an ulcerous disease, and 5-6% will have premalignant changes on the gastric mucosa and even gastric cancer in 1% of the cases, the goal to detect and treat H. pylori infection is, in our opinion, very much justified by both theoretical and practical reasons. Diagnosis methods for the infection's detection are numerous and diverse, the choice for one or another depending on several factors, among which: accessibility, advantages and disadvantages specific to each method (particularly the method's invasive or non invasive character), the cost, the aim (diagnosis, epidemiological, the treatment's efficiency, etc.). From a clinical point of view the patient's age, antecedents and digestive symptoms, as well as his psychological state and associated treatments are also important. Once the diagnosis of infection is proved, the treatment of the Helicobacter pylori infection supposes the simultaneous administration of antibiotics and proton pump inhibitors. The idea to create a vaccine for Helicobacter pylori is the evident result of the need to avoid the costs imposed by the diagnosis and treatment of the infection, especially in view of the high percentage of failure in eradicating the infection. If we add to these the socio-economic costs brought by the treatment of gastric ulcers and cancers, the idea of using a vaccine with double role, both in preventing, as well as in treating the infection, is even more attractive.


Assuntos
Infecções por Helicobacter/diagnóstico , Infecções por Helicobacter/terapia , Antibacterianos/uso terapêutico , Antígenos de Bactérias/análise , Vacinas Bacterianas , Quimioterapia Combinada , Fezes/microbiologia , Infecções por Helicobacter/tratamento farmacológico , Infecções por Helicobacter/prevenção & controle , Helicobacter pylori , Humanos , Inibidores da Bomba de Prótons/administração & dosagem , Urease/metabolismo
9.
Rom J Intern Med ; 48(3): 271-80, 2010.
Artigo em Inglês | MEDLINE | ID: mdl-21528754

RESUMO

Gastric cancer is one of the most aggressive malignancies, as incidence and as evolution as well. Although, due to the new findings about etiology, carcinogenesis, precancerous conditions and their detection, as well as the treatment, in the latest decade, there is an improvement in these data, gastric cancer remains a redoubtable enemy because of its incidence, prevalence and mortality. Researches are focusing on early detection of precursor lesions and on establishing their reversibility potential by bringing more clinical and statistical information and by setting new clinical hypotheses. In this context, the present article is trying to study immunohistochemical expression of two oncogenic markers, the cell adhesion protein antibodies E-cadherin and beta-catenin. Cell to cell and cell to extracellular matrix interactions are crucial for neoplastic transformation and for metastasizing process. The importance of these antibodies in maintaining cell adhesion suggests that their abnormal expression is playing an important role in tumorigenesis. In this article, authors are presenting a study about E-cadherin and beta-catenin expression in 75 patients who underwent gastrectomy for suspicions of gastric malignancies. The variables of the study are the presence or absence of Helicobacter pylori, type I carcinogenetic agent for gastric carcinoma (especially intestinal type adenocarcinoma) and the presence of tumoral or non-tumoral gastric lesions.


Assuntos
Adenocarcinoma/metabolismo , Caderinas/metabolismo , Infecções por Helicobacter/metabolismo , Neoplasias Gástricas/metabolismo , beta Catenina/metabolismo , Membrana Celular/metabolismo , Comorbidade , Infecções por Helicobacter/epidemiologia , Helicobacter pylori , Humanos , Imuno-Histoquímica , Neoplasias Gástricas/epidemiologia , Neoplasias Gástricas/microbiologia
10.
Rom J Intern Med ; 48(4): 347-53, 2010.
Artigo em Inglês | MEDLINE | ID: mdl-21528764

RESUMO

A 27-year-old male with a 2 year history of ankylosing spondylitis (AS) was investigated for intermittent episodes of diarrhea and found to have granulomatous ileitis. Differential diagnosis, discussions regarding similarities in immune alterations in both AS and Crohn's disease and therapeutic options are presented in this paper.


Assuntos
Ileíte/diagnóstico , Ileíte/tratamento farmacológico , Espondilite Anquilosante/diagnóstico , Espondilite Anquilosante/tratamento farmacológico , Corticosteroides/uso terapêutico , Adulto , Ácidos Aminossalicílicos/uso terapêutico , Antibacterianos/uso terapêutico , Anti-Inflamatórios não Esteroides/uso terapêutico , Antirreumáticos/uso terapêutico , Terapia Biológica , Doença de Crohn/diagnóstico , Diagnóstico Diferencial , Humanos , Masculino
11.
Rom J Intern Med ; 47(1): 75-85, 2009.
Artigo em Inglês | MEDLINE | ID: mdl-19886073

RESUMO

The gut can play an important role in the pathogenesis of many rheumatic conditions; this is also true for spondyloarthropathies, ileocolonoscopic studies revealing the prevalence of histological gut inflammation in more than half of these patients. Furthermore, in patients with spondyloarthritis, an evolution to clinical inflammatory bowel disease has been observed in 20% of patients with an initial subclinical chronic gut inflammation, indicating that joint and bowel inflammation are somehow connected. The presence of chronic gut inflammation can be the first sign of Crohn's disease, and it is being speculated that early treatment of the gut inflammation could prevent this evolution when the appropriate drugs become available. Moreover, the medication employed in treating these patients has the potential of influencing the inflammatory bowel lesions, in a negative (NSAIDs) or positive way (DMARDs, corticosteroids, biologic agents), and there are reports trying to prove that the spondylarthropathic ileo-colonic inflammation represents, at least in part, iatrogenic COX-2 driven damage. Therefore, there are "obscure" fields regarding the issue of gut inflammation in spondyloarthropathies, which need focused research, but taking into consideration the complex treatment strategies applied in patients with these kinds of diseases, this is not an easy task to perform.


Assuntos
Doenças Inflamatórias Intestinais/complicações , Espondilartrite/complicações , Anti-Inflamatórios não Esteroides/efeitos adversos , Antirreumáticos/efeitos adversos , Humanos , Mucosa Intestinal/efeitos dos fármacos , Espondilartrite/tratamento farmacológico
12.
Rom J Intern Med ; 47(1): 87-92, 2009.
Artigo em Inglês | MEDLINE | ID: mdl-19886074

RESUMO

Involuntary weight loss is an important clinical condition that has not been extensively covered in the medical literature. Searching MEDLINE, we identified twelve case series in different regions of the world, mostly in developed countries. Three series included ambulatory patients, while nine studied patients from secondary care hospitals. A quarter of patients with involuntary weight loss had a cancer, and many had psychiatric diseases. Organic causes of involuntary weight loss are usually revealed by a basic evaluation, and a normal result is generally reassuring. In this case it is recommended a watchful surveillance instead of blind investigations, because the prognosis of IWL of undetermined cause is good. On the contrary, patients with involuntary weight loss caused by cancers have a severe prognostic due to the advanced stage of the disease. On the other way, these patients are easy to diagnose.


Assuntos
Neoplasias Gastrointestinais/complicações , Redução de Peso , Anemia Ferropriva/etiologia , Humanos , Transtornos Mentais/complicações
13.
Curr Health Sci J ; 35(4): 225-7, 2009 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-24778821

RESUMO

Fibrosis is the liver's scarring response to injury, culminating in cirrhosis and its complications. Percutaneous liver biopsy with connective tissue stain is considered more likely a ''silver'', rather than a ''gold standard'' for assessing the degree of hepatic fibrosis. That's why new modalities were recently developed to accurately assess the stage of the liver disease. The term ''elastography'' describes an imaging technique that conveys information about a tissue's relative firmness in response to compression, meaning it is more akin to palpation than inspection. Real-time transabdominal elastography represents a new technology for measurement of tissue elasticity integrated in ultrasound systems and can be performed with conventional ultrasound probes during a routine sonography examination. Some of its limitations are that it cannot explore neither all the patients, nor a sufficient size of the liver. In order to overcome these, now that the technology exists, we propose an endoscopic approach from the "inside".

14.
Rom J Intern Med ; 44(2): 117-30, 2006.
Artigo em Inglês | MEDLINE | ID: mdl-17236293

RESUMO

The treatment of chronic viral hepatitis is based mainly on interferon therapy. This therapy has many drawbacks, among which potentially dangerous side-effects. Moreover, the majority of the patients are asymptomatic at the time of diagnosis, and most of them will never develop cirrhosis, liver failure or hepatocellular carcinoma, making the decision to treat a difficult one. Currently, the best method of selection is liver biopsy, considered "the gold standard" for recommending antiviral treatment. The histological aspect can vary in different hepatic areas and the smaller the bioptic fragment, the more probable is the histopathologist's error in correctly defining the hepatitis. There has been made important progress in defining the degree of liver involvement using serological tests, with the purpose of avoiding liver biopsy, but this approach has not yet proven to be superior. At present, the benefits of the pretreatment liver biopsy outbalance the risks. The future developments in the domain of antiviral drugs or nonhistological tests for evaluating the liver injury (circulating cytokines, subtypes of collagen) will show if the liver biopsy could be abandoned.


Assuntos
Hepatite C Crônica/patologia , Fígado/patologia , Antivirais/efeitos adversos , Antivirais/uso terapêutico , Biópsia , Carcinoma Hepatocelular/prevenção & controle , Hepatite C Crônica/sangue , Hepatite C Crônica/complicações , Hepatite C Crônica/tratamento farmacológico , Humanos , Interferon Tipo I/efeitos adversos , Interferon Tipo I/uso terapêutico , Fígado/metabolismo , Cirrose Hepática/prevenção & controle , Neoplasias Hepáticas/prevenção & controle , Valor Preditivo dos Testes , Proteínas Recombinantes
15.
Rom J Intern Med ; 42(1): 59-67, 2004.
Artigo em Inglês | MEDLINE | ID: mdl-15529595

RESUMO

The outcome of the HBV and HCV infections is influenced by the status of the immune system. Both of the viruses are believed not to be directly cythopathic, and the host immune response is responsible for the viral clearance and cellular injury. An energic response of the natural immunity allows the control of the virus. Rapid development of specific neutralizing antibodies is essential for the clearance of VHB. The chronic phase of the disease is often associated with abnormal and weak T-cell response and viral persistence. The pathogenesis of the HCV infection is not yet completely understood. HCV persists in patients without any apparent evidence of immune deficits depending on virus or host-related factors. The recent studies revealed that both cellular and humoral immunity appear to be active, despite the progression of the disease.


Assuntos
Hepatite B/imunologia , Hepatite B/patologia , Hepatite C/imunologia , Hepatite C/patologia , Formação de Anticorpos , Biomarcadores/análise , Humanos , Imunidade Celular
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA